Raltegravir in vitro effect on bilirubin binding

Area of Science:

• Neonatal pharmacology
• Drug metabolism and interactions
• Clinical toxicology

Background:

• Neonatal jaundice is common, and certain drugs can exacerbate it by displacing bilirubin from albumin.
• Kernicterus, a severe form of neonatal jaundice, poses significant health risks.
• Understanding drug interactions with bilirubin binding is crucial for neonatal safety.

Purpose of the Study:

• To investigate the in vitro effect of raltegravir on bilirubin-albumin binding in neonatal serum.
• To assess the potential risk of kernicterus associated with raltegravir use in neonates.
• To determine the clinical relevance of raltegravir's impact on bilirubin binding.

Main Methods:

• Pooled neonatal serum was used for in vitro testing.
• The peroxidase method was employed to measure bilirubin-albumin binding.
• Raltegravir was tested at various concentrations (5, 10, 100, 500, and 1000 µM).

Main Results:

• Raltegravir exhibited minimal effect on bilirubin-albumin binding at low concentrations (5 and 10 µM).
• A small, statistically significant increase in unbound bilirubin was observed at 100 µM.
• Potentially harmful increases in unbound bilirubin occurred at higher concentrations (500 and 1000 µM).

Conclusions:

• The effect of raltegravir on neonatal bilirubin binding is unlikely to be clinically significant at typical peak concentrations achieved with standard dosing.
• Raltegravir appears to have a relatively safe profile regarding bilirubin displacement in neonates.
• Further clinical studies may be warranted to confirm these findings in vivo.